Who is sponsoring NCT04634344?

NCT04634344 is sponsored by Dizal Pharmaceuticals.

What drugs are being tested in NCT04634344?

Interventions in NCT04634344: DZD2269.

What condition does NCT04634344 study?

NCT04634344 studies Metastatic Castration Resistant Prostate Cancer.

Is NCT04634344 still recruiting?

NCT04634344 is currently terminated. Last updated 11 July 2022.

Last reviewed 2022-07-11 · How we verify

NCT04634344

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

Terminated Phase 1 Last updated 11 July 2022

What this trial tests

Phase 1 trial testing DZD2269 in Metastatic Castration Resistant Prostate Cancer in 16 participants. Terminated before completion.

Timeline

12 April 2021

Primary endpoint
5 May 2022

5 May 2022

Quick facts

Lead sponsor	Dizal Pharmaceuticals
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	12 April 2021
Primary completion	5 May 2022
Estimated completion	5 May 2022
Sites	6 locations across United States, South Korea

Drugs / interventions tested

DZD2269 — full drug profile →

Conditions studied

Metastatic Castration Resistant Prostate Cancer — all drugs for Metastatic Castration Resistant Prostate Cancer →

Sponsor

Dizal Pharmaceuticals — full company profile →

Who can join

18 and older, male only, with Metastatic Castration Resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will treat patients with Metastatic Castration Resistant Prostate Cancer who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.
Bai Y, Zhang X, Zheng J, Liu Z, et al · · 2022 · cited 21× · PMID 36229853 · DOI 10.1186/s13046-022-02511-1
The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy.
Cruz-Bermúdez A, Laza-Briviesca R, Casarrubios M, Sierra-Rodero B, et al · · 2021 · cited 12× · PMID 33807260 · DOI 10.3390/biomedicines9040361
[Blocking Adenosine/A2AR Pathway for Cancer Therapy].
Liu J, Shi Y, Liu X, Zhang D, et al · · 2022 · cited 7× · PMID 35899442 · DOI 10.3779/j.issn.1009-3419.2022.102.24

Verify or expand the search:

Other trials of DZD2269

Trials testing the same drug.

NCT04932005 — A Study of DZD2269 in Healthy Adult Participants · Phase 1 · completed

Other recruiting trials for Metastatic Castration Resistant Prostate Cancer

Currently open trials in the same condition.

NCT07093801 — Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer · recruiting
NCT06830850 — A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With · Phase 1 · recruiting
NCT06517719 — Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer · recruiting
NCT05219500 — Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate C · Phase 2 · active not recruiting
NCT04729114 — A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer · Phase 1 · recruiting

Other Dizal Pharmaceuticals trials

Trials by the same sponsor.

NCT06813365 — Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2) · Phase 1 · recruiting
NCT07234162 — A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) · Phase 3 · recruiting
NCT06084104 — DZD9008 PK Study in Hepatic Impairment Subjects · Phase 1 · completed
NCT05926180 — Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and · Phase 1 · completed
NCT05824585 — DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04634344 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dizal Pharmaceuticals
Last refreshed: 11 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04634344.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing